Abstract:
Objective To explore new therapy for tumor patients of who had got gastroesophageal reflux disease(GERD)and reflux esophagitis(RE).
Methods Fourteen hospitalized cancer patients of who had got refractory GERD and combined with RE, were enrolled in this study.All the patients were invalid to a variety of drug treatment for more than 8 weeks.All of them had taken several kinds of drugs before this study, including omeprazole or rabeprazole、ranitidine or famotidine、mosapride.Adding selective cyclooxygenase-2(cyclo-oxygen-ase 2)inhibitors celecoxib used with 200 or 400 mg bid, and taking gentamicin、clarithromycin sustained-release tablets at the same time for 14 days.
Results Symptoms were improved: all of the 14(100%)patients got better in 3~7 days.The symptoms such as belching, acid reflux, " heartburn" feeling, sternum or sword burning, loss of appetite, and no supine at night were significantly improved.Disappeared Symptom: 12(85.71%)of them got completely relieved while the other two discharged from hospital in less than 14 days.Symptom relapsed: two(14.29%).
Conclusion Mach researches have confirmed GERD and RE occurrence, development and its degree was positively correlated with high expression of COX-2, therefore, adding COX-2 inhibitor-Celecoxib on the basic therepy schedule could enhance the therepy effect of refractory GERD and RE among cancer patients.
Key words:
Gastroesophageal reflux,
Esophagitis,
Medication,
Cyclooxygenase-2 inhibitors
Xuxun He, Yan Chen, Wenyue Yan, Rong Yang, Yunxiang Sun. Target therapy by celecoxib to gastroesophageal reflux disease and reflux esophagitis in tumor patients[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2016, 03(03): 117-120.